We protect our product candidates through the use of patents, trade secrets and careful monitoring of our proprietary know-how. Our patent portfolios are wholly owned by us. They include issued patents or patent applications that claim deuterated analogs of nearly 100 non-deuterated drugs and drug candidates.
The U.S. Patent and Trademark Office (USPTO) has issued 98 patents relating to Concert’s DCE Platform. Additionally, our patent portfolio includes numerous issued foreign patents including issuances in Europe, Japan, China, Australia, and Russia, among other territories.